Standout Papers
Citation Impact
Citing Papers
Noninvasive Urinary Metabolomic Profiling Identifies Diagnostic and Prognostic Markers in Lung Cancer
2014
Three-Gene Prognostic Classifier for Early-Stage Non–Small-Cell Lung Cancer
2007
NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma
2015
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non–Small-Cell Lung Cancer
2011
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Prognostic PET 18F-FDG Uptake Imaging Features Are Associated with Major Oncogenomic Alterations in Patients with Resected Non–Small Cell Lung Cancer
2012
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
Cancer statistics, 2023
2023 Standout
Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer
2004
Guidelines for the welfare and use of animals in cancer research
2010 Standout
Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo
2010
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
2020 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Cancer statistics, 2024
2024 Standout
Cell mechanics and the cytoskeleton
2010 StandoutNature
EGFR Antagonists in Cancer Treatment
2008 Standout
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
2012
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
2019 Standout
Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection
2018
Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: Controversies, insights, and changing horizons
2014
Immunotherapy as a strategy for the treatment of non-small-cell lung cancer
2010
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
A view on drug resistance in cancer
2019 StandoutNature
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
Mediastinal Lymph Node Dissection versus Mediastinal Lymph Node Sampling for Early Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
2014
Guidelines on the radical management of patients with lung cancer
2010
The biology and management of non-small cell lung cancer
2018 StandoutNature
Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non-small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis of Randomized Trials
2009
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
Thymoquinone: Potential cure for inflammatory disorders and cancer
2011 Standout
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer
2004
Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
2013
Maximizing clinical benefit with trastuzumab
2004
Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer
2007
British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)
2017 Standout
Glutaminase 1 expression in colorectal cancer cells is induced by hypoxia and required for tumor growth, invasion, and metastatic colonization
2019 StandoutNobel
Molecular mechanisms of cisplatin resistance
2011 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
The function of terpene natural products in the natural world
2007 Standout
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Mortality due to cancer treatment delay: systematic review and meta-analysis
2020 Standout
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
2018 Standout
Metabolomics: beyond biomarkers and towards mechanisms
2016 Standout
GRADE guidelines 6. Rating the quality of evidence—imprecision
2011 Standout
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer
2004
Efficacy of EGFR Tyrosine Kinase Inhibitors in the Adjuvant Treatment for Operable Non-small Cell Lung Cancer by a Meta-Analysis
2015
Microtubules as a target for anticancer drugs
2004 Standout
Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review
2011
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Prognostic impact of serum albumin levels on the recurrence of stage I non-small cell lung cancer
2013
Development of novel therapeutic strategies that target HIF-1
2006 StandoutNobel
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
2014 Standout
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
2012 Standout
Fusobacterium nucleatum — symbiont, opportunist and oncobacterium
2018 Standout
MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer
2010
Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer
2010
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
2014 Standout
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
2009 Standout
Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management.
2008
Dissecting intratumoral myeloid cell plasticity by single cell RNA‐seq
2019
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery
2017
Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer
2008
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
2017 Standout
Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy
2012
Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10
2009
Role of Postoperative Radiotherapy in Resected Non-Small Cell Lung Cancer: A Reassessment Based on New Data
2011
Perioperative Systemic Therapy for Resectable Non–Small Cell Lung Cancer
2022
Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results
2013
Combination therapy in combating cancer
2017 Standout
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
2014 StandoutNobel
Patient-Derived First Generation Xenografts of Non–Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy
2010
The Versatile Role of microRNA-30a in Human Cancer
2017 Standout
Human Infection withFusobacterium necrophorum(Necrobacillosis), with a Focus on Lemierre's Syndrome
2007
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update
2017
Treatment of Advanced Non–Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel
2005
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data
2010
Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America
2012 Standout
Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection
2015
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
2007
Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients
2005
Molecular Origin of Blood‐Based Infrared Spectroscopic Fingerprints**
2021 StandoutNobel
Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art.
2015
Works of D. Aubert being referenced
Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial
2006
GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine–cisplatin with vinorelbine–ifosfamide–cisplatin in metastatic non-small-cell lung cancer patients
2002
Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation
2010
Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial
2004
Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer
2003
A multinational phase II study of Navelbine (N) and Herceptin (H) as first-line therapy for patients with HER2-positive metastatic breast cancer (HER2+ MBC)
2004
[Streptococcus intermedius Lemierre syndrome: an unusual association].
2000
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
2008 Standout
Evaluation of the efficacy of prophylactic intravenous antibiotherapy with ceftriaxone in post-chemotherapy agranulocytic patients.
1990
Pr3 ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I–III) non small cell lung cancer (NSCLC) patients (pts)
2005
Evaluation of vinorelbine (N) and trastuzumab (H) as first-line therapy for patients (pts) with HER2- positive metastatic breast cancer (HER2+ MBC): Impact on clinical response and cardiac function
2004